Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actions
No regulatory agency, including the FDA, has notified the Company of a clinical hold in any of its clinical trials
Observed decreased rate of successful manufacturing of ITIL-168 for patients recently enrolled in DELTA-1 trial
Company intends to provide an update on the manufacturing analysis by early Q1 2023
Company confirms cash runway into 2025 upon the successful completion of a potential sale-leaseback transaction of its Tarzana manufacturing facility
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.